Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.38 |
| ▸ | PSMB5 | P28074 | 3/20 | 0.37 |
| ▸ | HRH1 | P35367 | 2/20 | 0.37 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.37 |
| ▸ | REN | P00797 | 4/20 | 0.36 |
| ▸ | CTSB | P07858 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | MMP1 | P03956 | 1/20 | 0.36 |
| ▸ | FCER2 | P06734 | 1/20 | 0.36 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26348504 | 0.88 | AKT1 (0.45) | AKT1PSMB5RENOPRD1 | |
| SCHEMBL24037988 | 0.87 | AKT1 (0.44) | AKT1PSMB5HRH1RENOPRD1 | |
| SCHEMBL25877236 | 0.86 | AKT1 (0.44) | AKT1PSMB5RENCTSBOPRD1 | |
| SCHEMBL25877257 | 0.86 | AKT1 (0.44) | AKT1PSMB5RENCTSBOPRD1 | |
| SCHEMBL25877071 | 0.86 | AKT1 (0.44) | AKT1PSMB5RENCTSBOPRD1 | |
| SCHEMBL26503041 | 0.83 | AKT1 (0.47) | AKT1PSMB5RENOPRD1 | |
| SCHEMBL26027305 | 0.82 | AKT1 (0.42) | AKT1EPHX2HRH1OPRD1 | |
| SCHEMBL26027432 | 0.82 | AKT1 (0.42) | AKT1EPHX2HRH1OPRD1 | |
| SCHEMBL26678546 | 0.82 | AKT1 (0.42) | AKT1EPHX2HRH1OPRD1 | |
| SCHEMBL27268350 | 0.82 | EPHX2 (0.44) | AKT1EPHX2PSMB5PSMB2REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018159-A1 | EXATECAN DERIVATIVES, LINKER-PAYLOADS, AND CONJUGATES AND THEREOF | GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD. (CN) | 2024-01-18 | — | — | US | disclosed |
| US-11814394-B2 | Exatecan derivatives, linker-payloads, and conjugates and thereof | GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD. (CN) | 2023-11-14 | — | — | US | disclosed |
| US-20230271977-A1 | EXATECAN DERIVATIVES, LINKER-PAYLOADS, AND CONJUGATES AND THEREOF | GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD. (CN) | 2023-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271977-A1 | EXATECAN DERIVATIVES, LINKER-PAYLOADS, AND CONJUGATES AND THEREOF | XPOT, ENGASE, ENTPD8 | AKT1 3247/4885EPHX2 1289/4885PSMB5 2171/4885 |
| US-11814394-B2 | Exatecan derivatives, linker-payloads, and conjugates and thereof | XPOT, ENGASE, ENTPD8 | AKT1 3247/4885EPHX2 1289/4885PSMB5 2171/4885 |
| US-20240018159-A1 | EXATECAN DERIVATIVES, LINKER-PAYLOADS, AND CONJUGATES AND THEREOF | XPOT, ENGASE, ENTPD8 | AKT1 3247/4885EPHX2 1289/4885PSMB5 2171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.